Endorsed by the CCM Georgia on April 15th 2015
Accessed: 26.09.2019
The Open Infectious Diseases Journal, 2013, 7, (Suppl 1: M6) 54-59
Tokar A, et al. Sex Transm Infect 2019;95:193–200. doi:10.1136/sextrans-2018-053684
UNAIDS 2018, Guidance
Indicators for monitoring the
2016 Political Declaration on Ending AIDS
InternatIonal Journal of adolescence and Youth
2019, Vol. 24, No. 3, 362–379
https://doi.org/10.1080/02673843.2018.1479278
PLOS ONE | DOI:10.1371/journal.pone.0144057 December 14, 2015
BMJ,Dodd PJ, et al. Thorax 2017;72:559–575. doi:10.1136/thoraxjnl-2016-209421
PLOS ONE | https://doi.org/10.1371/journal.pone.0210937
February 5, 2019
PLOS ONE | https://doi.org/10.1371/journal.pone.0196380 May 15, 2018
Guidance Brief
Selected findings from ECDC and EMCDDA scientific guidance, 2018
Unite for Children
First Edition
This briefing paper provides an overview of pre-exposure prophylaxis (PrEP) for people planning, commissioning or providing HIV prevention activities in the UK. It does this by reviewing thirty key questions about PrEP and how it might be implemented in the UK.
This document provides guidance on the application of non-pharmaceutical countermeasures to minimise the spread of the 2019 novel coronavirus (2019-nCoV) in the population. Some of the measures proposed refer specifically to certain phases of the epidemic (containment or mitigation phases), and can ...be adapted depending on the assessed severity/impact of the infection. Other measures are valid for all phases of an epidemic.
The guidance is based on the current knowledge of the 2019-nCoV and evidence available on other viral respiratory pathogens, mainly the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), the Middle East Respiratory Syndrome-related coronavirus (MERS-CoV) and seasonal or pandemic influenza viruses.
more
Research Article
Karo et al. BMC Infectious Diseases 2014, 14:148 http://www.biomedcentral.com/1471-2334/14/148